Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eagle Capital Growth Fund (GRF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.44 +1.61%
on 12/11/19
8.32 -9.13%
on 11/12/19
-0.69 (-8.38%)
since 11/11/19
3-Month
7.44 +1.61%
on 12/11/19
8.45 -10.53%
on 10/10/19
-0.35 (-4.42%)
since 09/11/19
52-Week
6.55 +15.42%
on 12/31/18
8.45 -10.53%
on 10/10/19
+0.02 (+0.27%)
since 12/11/18

Most Recent Stories

More News
Grifols presents its latest Alzheimer's clinical trial data

Neuroimaging shows AMBAR clinical trial's positive effects in patients with mild-to-moderate Alzheimer's disease

GRFS : 22.80 (+0.53%)
GRF : 7.56 (+0.27%)
Grifols presents its latest Alzheimer's clinical trial data

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, today concluded more than a year of encouraging results of its AMBAR (Alzheimer Management by Albumin...

GRF : 7.56 (+0.27%)
GRFS : 22.80 (+0.53%)
Grifols Streamlines Hospital Pharmacy Operations With New KIRO Fill® Technology and PharmacyKeeper Enhancements

Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announced...

GRF : 7.56 (+0.27%)
GRFS : 22.80 (+0.53%)
Grifols Streamlines Hospital Pharmacy Operations With New KIRO Fill® Technology and PharmacyKeeper Enhancements

BARCELONA, Spain , Dec. 5, 2019 /PRNewswire/ --   Grifols   (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and...

GRFS : 22.80 (+0.53%)
GIKLY : 16.9800 (-0.93%)
GIFOF : 22.8000 (+1.95%)
GIFLF : 34.1900 (+4.72%)
GRF : 7.56 (+0.27%)
Grifols to present latest Alzheimer's clinical trial results

Grifols , a leading global producer of plasma-derived medicines, will present the final and complete clinical, biomarker and neuroimaging results of its AMBAR (Alzheimer Management by Albumin Replacement)...

GRFS : 22.80 (+0.53%)
GRF : 7.56 (+0.27%)
Grifols to present latest Alzheimer's clinical trial results

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, will present the final and complete clinical, biomarker and neuroimaging results of its AMBAR (Alzheimer...

GRF : 7.56 (+0.27%)
GRFS : 22.80 (+0.53%)
Grifols introduces AlphaID(TM), a free cheek swab to screen for Alpha-1, the most common genetic form of COPD

Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, has now introduced AlphaID(TM), a...

GRF : 7.56 (+0.27%)
GRFS : 22.80 (+0.53%)
Grifols Procleix Panther System With Automation Ready Technology (ART) Receives CE-mark

- ART enables greater workflow efficiency and lean sample management, supporting laboratories' path towards total automation

GRFS : 22.80 (+0.53%)
GRF : 7.56 (+0.27%)
Grifols presents additional encouraging Alzheimer's trial results at AAIC

The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial for the treatment of Alzheimer's...

GRF : 7.56 (+0.27%)
GRFS : 22.80 (+0.53%)
Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies

Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S....

GRF : 7.56 (+0.27%)
GRFS : 22.80 (+0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

GRF Dividends

Date Value
11/21/19 $0.5600
11/21/18 $0.5300
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar